Guillaume P Nicolas
Overview
Explore the profile of Guillaume P Nicolas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
524
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chirindel A, Nicolas G, Westerbergh F, McDougall L, Schmid D, Geistlich S, et al.
Eur J Nucl Med Mol Imaging
. 2024 Dec;
PMID: 39633183
No abstract available.
2.
Schurrle S, Eberlein U, Ansquer C, Beauregard J, Durand-Gasselin L, Gronbaek H, et al.
Eur J Nucl Med Mol Imaging
. 2024 Mar;
51(8):2428-2441.
PMID: 38528164
Purpose: To evaluate the dosimetry and pharmacokinetics of the novel radiolabelled somatostatin receptor antagonist [Lu]Lu-satoreotide tetraxetan in patients with advanced neuroendocrine tumours (NETs). Methods: This study was part of a...
3.
Fricke J, Westerbergh F, McDougall L, Favaretto C, Christ E, Nicolas G, et al.
Eur J Nucl Med Mol Imaging
. 2024 Mar;
51(8):2517-2519.
PMID: 38448550
No abstract available.
4.
Hench I, Roma L, Conticelli F, Bubendorf L, Calgua B, Le Magnen C, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201475
Most men with prostate cancer (PCa), despite potentially curable localized disease at initial diagnosis, progress to metastatic disease. Despite numerous treatment options, choosing the optimal treatment for individual patients remains...
5.
Neubauer M, Nicolas G, Bauman A, Fani M, Nitzsche E, Afshar-Oromieh A, et al.
Eur J Nucl Med Mol Imaging
. 2023 Dec;
51(4):1185-1193.
PMID: 38038755
Purpose: To assess early tumor response with quantitated SPECT/CT and to correlate it with clinical outcome in metastatic castration-resistant prostate cancer (mCRPC) patients treated with Lutetium-PSMA I&T therapy. Methods: Single-center,...
6.
7.
Wild D, Gronbaek H, Navalkissoor S, Haug A, Nicolas G, Pais B, et al.
Eur J Nucl Med Mol Imaging
. 2023 Sep;
51(1):183-195.
PMID: 37721581
Purpose: We present the results of an open-label, phase I/II study evaluating the safety and efficacy of the novel somatostatin receptor (SSTR) antagonist [Lu]Lu-satoreotide tetraxetan in 40 patients with previously...
8.
Mallaev M, Chirindel A, Lardinois D, Tamm M, Vija A, Cachovan M, et al.
Clin Lung Cancer
. 2023 Aug;
24(7):621-630.
PMID: 37544842
Objectives: Based on previous studies, single-photon emission computed tomography/computed tomography (SPECT/CT) has been proven more accurate and reproducible than planar lung perfusion scintigraphy to assess lobar perfusion. However, the impact...
9.
The Emergence of Somatostatin Antagonist-Based Theranostics: Paving the Road Toward Another Success?
Imperiale A, Jha A, Meuter L, Nicolas G, Taieb D, Pacak K
J Nucl Med
. 2023 Feb;
64(5):682-684.
PMID: 36759198
No abstract available.
10.
Fani M, Mansi R, Nicolas G, Wild D
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267479
Somatostatin receptors (SSTs) are recognized as favorable molecular targets in neuroendocrine tumors (NETs) and neuroendocrine neoplasms (NENs), with subtype 2 (SST) being the predominantly and most frequently expressed. PET/CT imaging...